A new study published in Nature: Scientific reports noted significant benefits for mood and mental health after one month of microdosing psilocybin mushrooms.
Mushroom microdosers saw major improvements in the DASS domains of Depression, AnxietyAnd Fatigue. The study indicates that they found no differences in these results between the sexes, but found that the cognitive efficacy of the microdose was more effective in people under the age of 55.
The study looked at 1,133 people over the course of two years. All subjects were over 18, could read English, and had access to an iPhone iOS device where participants recorded their results. Scientific reports is an open access peer-reviewed scientific journal published online by Natura portfolio.
The study was conducted by a team of experts in the field of psychology and mycology: Joseph M. Rootman, Department of Psychology, University of British Columbia, Kelowna, BC, Canada; Maggie Kiraga, a Quantified Citizen Technologies employee. Pamela Kryskow, member of the clinical advisory board of Numinus Wellness, co-founder of MycoMedica Life Sciences, and of the scientific and medical advisory board; Kalin Harvey; Paul Stamets, who founded Fungi Perfecti, LLC; Eesmyal Santos-Brault; Kim PC Kuypers; and Zach Walsh, member of the Advisory Board of the Multidisciplinary Association for Psychedelic Studies (MAPS) Canada and MycoMedica Life Sciences.
“This study is an extension of our previous manuscript published in the same journal and we have further publications in preparation based on this same study,” says University of British Columbia Psychology Department researcher Joseph Rootman. He says the team plans to continue this line of research and expand these findings in the future. “Our team also worked hard to develop the next version of the study that will be used to generate psychedelic microdosing results for years to come.”
There is no specific type of fungus, or strain, that the study used because it was “observational in nature,” says Rootman. The researchers did not provide psilocybin mushrooms to the participants, but observed and recorded the participants’ experiences as they engaged in their “Microdose practice”.
“In this initial version of the study, we didn’t ask the participants specifically which strain of mushrooms they were using. Although we have collected data on a practice called stacking where psilocybin mushrooms are combined with other non-psychedelic substances such as lion’s mane mushrooms or chocolate, “says Rootman.” Our first study found that about half of the micro dosers in our sample were stacked with a large variety of substances, while our most recent study extended these findings by noting associated improvements in psychomotor ability among stacked microdosers compared to non-stackable or non-microdosing peers. “
So how exactly is a psilocybin microdose considered? The team seemed previous. “Based on previous psilocybin microdosing studies, we classified participants’ responses to psilocybin dosing into low, medium and high microdoses corresponding to ≤ 0.1 grams of dried mushrooms, 0.1-0.3 grams of mushrooms, respectively. dried, ≥ 0.3 grams of dried mushrooms, “says Rootman. Most of the participants landed somewhere in the mid range of 0.1-0.3 grams of psilocybin. “We found that approximately 10% of our microdosing sample in this study reported high dosages, 72.6% reported medium dosages, and 16.8% reported low dosages.”
These findings join the ranks of many legitimate and peer-reviewed academic studies that consider psilocybin a promising treatment for depression. The Journal of Psychopharmacology published a follow-up earlier this year to this widely publicized study from Johns Hopkins Medicine which found that psilocybin can continue to help people with depression for up to a year later.